About Type 2 Diabetes
Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT.
The Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019.
Read more details at: http://www.bigmarketresearch.com/global-type-2-diabetes-therapeutics-2015-2019-market
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Type 2 Diabetes Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of following drugs:
• DPP-4 inhibitors
• Biguanides
• Insulins
• GLP-1 receptor agonists
• Thiazolidenediones
• Sulfonulureas
• SGLT-2 inhibitors
• a-Glucosidase inhibitors
• Others (amylinomimetics, bile acid sequestrants, and dopamine receptor agonists)
Further, the territories considered in the report include:
• Americas (US, Brazil, and Mexico)
• 5EU (France, Germany, Italy, Spain, and UK)
• APAC (China, Japan, India, Russia, and other APAC countries)
Global Type 2 Diabetes Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from...